Naramig (Naratriptan)

Naratriptan, the active ingredient in Naramig, is a triptan presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is a triptan medication used in the acute treatment of migraine attacks.

Migraine (with aura): provides rapid relief of headache and associated symptoms. Migraine (without aura): reduces pain intensity and duration of the attack. Acute migraine attacks: helps patients achieve functional recovery during an episode.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient feeling of light‑headedness. - Tingling or numbness: usually in the extremities. - Dry mouth: reduced salivation. - Fatigue: feeling unusually tired. - Chest discomfort: pressure or tightness in the chest.

Serious or Rare Side Effects: - Coronary vasospasm: sudden narrowing of heart arteries. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Severe hypertension: abrupt increase in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Myocardial infarction: heart attack in susceptible individuals. - Cardiac arrhythmias: irregular heart rhythms.

Before using Naramig, consider the following precautions.

Cardiovascular assessment: evaluate history of heart disease or risk factors. Uncontrolled hypertension: avoid if blood pressure is not well managed. Serotonergic drugs: use caution when co‑administered with SSRIs, SNRIs, or MAO inhibitors. Dose limits: do not exceed the prescribed maximum daily dose. Operating machinery: refrain from driving or using heavy equipment if drowsy. Store at ambient temperature: keep in the original container, protect from moisture.

Naratriptan may interact with several medication classes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome. - Other triptans: increased risk of vasospasm. - Ergot alkaloids: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - SSRIs/SNRIs: monitor for signs of serotonin excess. - CYP3A4 inhibitors (e.g., ketoconazole): may increase naratriptan levels. - Oral contraceptives: may slightly elevate plasma concentrations.